TP53 alterations are relatively uncommon in myeloid neoplasms (MN), accounting for 8%–10% of myelodysplastic syndrome (MDS) and 10%–12% of acute myeloid leukemia (AML) cases [2, 3, 4, 5, 6]. Here, TP53 is linked to myelodysplastic syndrome.